PRIME MEMBER EXCLUSIVE | 3 Months Free Trial
Auto-renews at INR 199/mo after 3 months. Cancel anytime. Offer ends 15 July, 2026.
ARASEC and Lead-in ADT - China focus
Failed to add items
Add to cart failed.
Add to wishlist failed.
Remove from wishlist failed.
Follow podcast failed
Unfollow podcast failed
ARASEC and Lead-in ADT - China focus
-
Narrated by:
-
Written by:
Two interesting papers caught the eye of our GU Cast China team this week; the first is the ARASEC trial which Dr Rana McKay read out in the Practice-Changing Plenary at the AUA Annual Meeting in Washington. This is an interesting comparison of ADT + darolutamide for mHSPC in a prospective US cohort, compared with an historical ADT-only control arm from CHAARTED. Interesting study design and interesting results.
The second is the ADT Lead-In study led bu GU Cast China Editor, Dr Yao Zhu, which demonstrates how the timing of docetaxel chemotherapy in mHSPC can significnatly affect the likelihood of severe neutropenia.
Your usual hosts, Declan Murphy and Renu Eapen, anre joined by Dr Yao Zhu (Fudan University, Shanghai), Dr Yige Bau (SCU Xiamen), and Dr Chuguan Yang (Tonji Hospital, Wuhan). Yige now also part of our GU Cast China team, looking after our We Chat content with Yao Zhu.
This is a Themed Podcast supported by our GU Cast China Partner, Bayer Pharmaceuticals.